ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
… oligonucleotides for severe genetic diseases through our innovation unit.” Financial Highlights At June 30, 2016, … preclinical development of QR-110 and progress of our innovation programs such as QR-313 for epidermolysis bullosa, …
… We have also made a lot of progress in advancing our innovation pipeline", said Daniel de Boer, Chief Executive … from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633545. About …
